At $850,000, price for new childhood blindness gene therapy four times too high, analysis says
The $850,000 list price for a new medicine that treats a genetic form of childhood blindness is about four times too high, a new analysis says.
The $850,000 list price for a new medicine that treats a genetic form of childhood blindness is about four times too high for the value the drug provides, a nonprofit that studies the cost-effectiveness of new drugs said Friday, though it added that the price of the drug is cost-effective for select patients and with certain assumptions.
from the Institute for Clinical and Economic for the U.S. market and the most expensive medicine by list price. It is in the debate over how to afford an innovative medicine — in this case, a therapy that corrects a genetic mutation in people’s cells — that carries, and in some views, deserves, a pricey list cost.
